Patterns of opioid dose escalation in patients with chronic kidney disease initiated on opioids for the treatment of non-cancer pain

Read full text Summarise with VIRAT
Authors: Che Suraya Zin, Stefania Lando, Ailema González-Ortíz, Viyaasan Mahalingasivam, Shayan Mostafaei, Wan Rohaidah Ahmad, Mazlila Meor Ahmad Shah, Björn Wettermark, Juan Jesus Carrera
Cited by: 0
References: 25

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

BACKGROUND: Pain management in chronic kidney disease (CKD) is challenging due to altered drug metabolism, impaired excretion, and higher opioid toxicity risk. Despite this, opioids are commonly prescribed, yet real-world data on dose escalation in CKD remain limited. OBJECTIVE: To investigate patterns and timing of opioid dose escalation to ≥50 and ≥90 MME/day among new opioid users across kidney function levels. METHODS: This population-based cohort study used data from the Stockholm Creatinine Measurements (SCREAM) project linking diagnoses, prescriptions, and laboratory records. Adult new opioid users (no prior opioid in 12 months) from 2012-2021 were categorized by baseline eGFR (≥60, 30-59, < 30 mL/min/1.73m²). Opioids were identified using ATC codes, and daily doses (MME/day) were calculated based on strength, quantity, and equianalgesic ratios. Fine-Gray competing-risks regression assessed time to dose escalation (≥50 and ≥90 MME/day), accounting for death as a competing event. RESULTS: Of 81,987 adult new opioid users, 5,987 (7.3%) escalated to ≥50 MME/day comprising 7.4%, 6.8%, and 8.1% of patients with eGFR ≥ 60, 30-59, and

Fields of Study & Subjects

Opioid Use Disorder Treatment Pain Management and Opioid Use Pharmaceutical Practices and Patient Outcomes

Publication details

Journal / source
PLoS ONE
Volume
21
Issue
3
Pages
e0345309–e0345309
Publication date
20 March 2026
Language
EN